Stereotactical Photodynamic Therapy With 5-aminolevulinic Acid (Gliolan®) in Recurrent Glioblastoma
Status:
Recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
In this multicenter, randomized, non-blinded trial the efficacy and safety of stereotactical
photodynamic therapy with 5-aminolevulinic acid will be investigated in 106 patients with
recurrent glioblastoma.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital Muenster
Collaborators:
Deutsche Krebshilfe e.V., Bonn (Germany) LifePhotonic GmbH medac GmbH photonamic GmbH & Co. KG